Nerys Dawn Forester1, Simon Lowes2, Elizabeth Mitchell3, Maureen Twiddy3. 1. Breast Screening and Assessment Unit, Royal Victoria Infirmary, Queen Victoria Road, Newcastle, NE1 4LP, UK. Electronic address: nerys.forester@nuth.nhs.uk. 2. Breast Screening and Assessment Unit, Queen Elizabeth Hospital, Gateshead, NE9 6SX, UK. 3. Hull York Medical School, Institute of Clinical and Applied Health Research, The Allam Medical Building, University of Hull, Hull, HU6 7RX, UK.
Abstract
INTRODUCTION: Provide evidence to support evolving management strategies for high-risk (B3) breast lesions by assessing risk of carcinoma in subgroups of B3 lesions using systematic review and meta-analysis. METHODS: Databases identified observational studies between 1980 and 2015 that reported on underestimation of malignancy following B3 lesion diagnosis at core needle biopsy. Critical appraisal, quality assessment, data extraction and meta-analysis was undertaken to calculate rate of malignancy of the whole B3 group and individual lesions. Study heterogeneity and association between variables and underestimation rate was investigated using random effects logistic modelling. RESULTS: Meta-analysis, using data from 129 studies, assessed 11 423 lesions of which 2160 were upgraded to malignancy after surgical excision biopsy (17% malignancy rate, 95% CI 15-19%). Malignancy rates varied from 6% in radial scars with no atypia (95% CI 2-13%, I2 72.8%), to 32% in papillomas with atypia (95% CI 23-41%, I2 57.4%). Differences in upgrade rates between atypical and non-atypical lesions were statistically significant (p < 0.05). Study heterogeneity could not be explained by differences in core biopsy size or year of publication. CONCLUSIONS: This comprehensive, inclusive assessment of all published literature, provides an accurate estimate of malignancy risk in subgroups of B3 lesions, to guide tailored management strategies. Some lesions have a high risk of malignancy, while others have a much lower risk, and could be safely managed with surveillance strategies rather than surgery. Crown
INTRODUCTION: Provide evidence to support evolving management strategies for high-risk (B3) breast lesions by assessing risk of carcinoma in subgroups of B3 lesions using systematic review and meta-analysis. METHODS: Databases identified observational studies between 1980 and 2015 that reported on underestimation of malignancy following B3 lesion diagnosis at core needle biopsy. Critical appraisal, quality assessment, data extraction and meta-analysis was undertaken to calculate rate of malignancy of the whole B3 group and individual lesions. Study heterogeneity and association between variables and underestimation rate was investigated using random effects logistic modelling. RESULTS: Meta-analysis, using data from 129 studies, assessed 11 423 lesions of which 2160 were upgraded to malignancy after surgical excision biopsy (17% malignancy rate, 95% CI 15-19%). Malignancy rates varied from 6% in radial scars with no atypia (95% CI 2-13%, I2 72.8%), to 32% in papillomas with atypia (95% CI 23-41%, I2 57.4%). Differences in upgrade rates between atypical and non-atypical lesions were statistically significant (p < 0.05). Study heterogeneity could not be explained by differences in core biopsy size or year of publication. CONCLUSIONS: This comprehensive, inclusive assessment of all published literature, provides an accurate estimate of malignancy risk in subgroups of B3 lesions, to guide tailored management strategies. Some lesions have a high risk of malignancy, while others have a much lower risk, and could be safely managed with surveillance strategies rather than surgery. Crown
Authors: Svjetlana Mohrmann; Anna Maier-Bode; Frederic Dietzel; Petra Reinecke; Natalia Krawczyk; Thomas Kaleta; Ulrike Kreimer; Gerald Antoch; Tanja N Fehm; Katrin Sabine Roth Journal: Breast Care (Basel) Date: 2021-07-01 Impact factor: 2.268
Authors: Roberto Lo Gullo; Kerri Vincenti; Carolina Rossi Saccarelli; Peter Gibbs; Michael J Fox; Isaac Daimiel; Danny F Martinez; Maxine S Jochelson; Elizabeth A Morris; Jeffrey S Reiner; Katja Pinker Journal: Breast Cancer Res Treat Date: 2021-01-20 Impact factor: 4.872
Authors: Ko Woon Park; Boo-Kyung Han; Sun Jung Rhee; Soo Youn Cho; Eun Young Ko; Eun Sook Ko; Ji Soo Choi Journal: Taehan Yongsang Uihakhoe Chi Date: 2021-10-18
Authors: Donato Casella; Daniele Fusario; Dario Cassetti; Simone Miccoli; Anna Lisa Pesce; Andrea Bernini; Marco Marcasciano; Federico Lo Torto; Alessandro Neri Journal: Breast J Date: 2020-06-28 Impact factor: 2.269
Authors: Janice Hui Ling Goh; Toh Leong Tan; Suraya Aziz; Iqbal Hussain Rizuana Journal: Int J Environ Res Public Health Date: 2022-01-11 Impact factor: 3.390